[go: up one dir, main page]

NO20063132L - Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer - Google Patents

Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer

Info

Publication number
NO20063132L
NO20063132L NO20063132A NO20063132A NO20063132L NO 20063132 L NO20063132 L NO 20063132L NO 20063132 A NO20063132 A NO 20063132A NO 20063132 A NO20063132 A NO 20063132A NO 20063132 L NO20063132 L NO 20063132L
Authority
NO
Norway
Prior art keywords
modulators
muscarinic receptors
naphthyridine derivatives
muscarinic
naphthyridine
Prior art date
Application number
NO20063132A
Other languages
English (en)
Inventor
Lewis R Makings
Peter D J Grootenhuis
Miguel Garcia-Guzman Blanco
Philip Martin Londo
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20063132L publication Critical patent/NO20063132L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En forbindelse av formel I, hvori: ring A er aryl eller heteroaryl; en av V, W, Y eller Z er nitrogen og de andre av V, W, Y og Z er -C(R5)-; modulerer muskariniske reseptorer og er egnet til behandling av muskariniske reseptorformidlede sykdommer.
NO20063132A 2003-12-09 2006-07-05 Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer NO20063132L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52804903P 2003-12-09 2003-12-09
PCT/US2004/040839 WO2005056552A1 (en) 2003-12-09 2004-12-07 Naphthyridine derivatives and their use as modulators of muscarinic receptors

Publications (1)

Publication Number Publication Date
NO20063132L true NO20063132L (no) 2006-09-11

Family

ID=34676813

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063132A NO20063132L (no) 2003-12-09 2006-07-05 Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer

Country Status (13)

Country Link
US (2) US7446112B2 (no)
EP (1) EP1709045A1 (no)
JP (1) JP2007513955A (no)
KR (1) KR20060123452A (no)
CN (1) CN1914204A (no)
AU (1) AU2004297241A1 (no)
CA (1) CA2548009A1 (no)
IL (1) IL176215A0 (no)
MX (1) MXPA06006532A (no)
NO (1) NO20063132L (no)
RU (1) RU2006124559A (no)
WO (1) WO2005056552A1 (no)
ZA (1) ZA200604721B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528441T3 (es) * 2010-02-22 2015-02-10 Merck Patent Gmbh Hetarilaminonaftiridinas
WO2011137049A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
WO2011159553A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
WO2012003147A1 (en) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
US9206200B2 (en) 2011-05-17 2015-12-08 Merck Sharp & Dohme Corp. N-linked lactam M1 receptor positive allosteric mogulators
EP2709624B1 (en) 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
EP2709621B1 (en) 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
WO2014117090A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP3206689B1 (en) 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
UY36714A (es) 2015-06-09 2016-12-30 Bayer Pharma Akttiengesellschaft Moduladores alostéricos positivos del receptor muscarínico m2
CN105646462B (zh) * 2016-01-19 2019-04-05 河南大学 芸香宁碱衍生物、其制备方法及应用
WO2017160670A1 (en) * 2016-03-16 2017-09-21 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulators and methods of use thereof
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
EP3296298A1 (de) * 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
EA038451B1 (ru) * 2016-12-06 2021-08-30 Байер Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновых кислот и их применение
US11066420B2 (en) * 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
US9855255B1 (en) 2017-05-26 2018-01-02 King Saud University Substituted naphthyridinyl hydrazines as anti-liver cancer agents
WO2022076975A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879799A (en) * 1998-02-26 1999-09-15 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
WO1999043682A1 (en) 1998-02-26 1999-09-02 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives, their preparation and their use as (ant-)agonists for gaba (a) brain receptors
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
ES2231158T3 (es) 1999-02-12 2005-05-16 Smithkline Beecham Plc Derivados y fenil urea y fenil tiourea.
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432222C (en) 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ITMI20012060A1 (it) * 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands

Also Published As

Publication number Publication date
CN1914204A (zh) 2007-02-14
IL176215A0 (en) 2006-10-05
JP2007513955A (ja) 2007-05-31
WO2005056552A1 (en) 2005-06-23
AU2004297241A1 (en) 2005-06-23
RU2006124559A (ru) 2008-01-20
US20050171141A1 (en) 2005-08-04
MXPA06006532A (es) 2006-08-23
CA2548009A1 (en) 2005-06-23
ZA200604721B (en) 2008-03-26
US20090042928A1 (en) 2009-02-12
KR20060123452A (ko) 2006-12-01
US7446112B2 (en) 2008-11-04
EP1709045A1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
NO20063132L (no) Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20050065L (no) Kjemiske forbindelser
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ATE302775T1 (de) Carbolinderivate
EP1669352A4 (en) THIAZOLINE DERIVATIVE AND ITS USE
NO20071073L (no) Heterocykel-substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20060870L (no) Fluorsubstituert omega-karboksyaryldifenylurea for behandling og profylakse av sykdommer og tilstander
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
NO20042024L (no) 4-(4-alkoksy-3-hydroksyfenyl)-2-pyrrolidonderivater som PDE4-inhibitorer for behandling av nevrologiske syndromer
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
NO20070570L (no) Forbindelser.
NO20055977L (no) Nye benzimidazolderivater
NO20055688L (no) Organiske forbindelser
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
ATE346067T1 (de) Carbolinderivate
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
NO20032841L (no) Heterocykloindol- eller azaindol-forbindelser som 5- hydroksytryptamin-6-ligander
NO20015669L (no) Heterocykliske substituerte aminoazacykler nyttige som sentralnervesystemmidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application